Literature DB >> 7166559

The analysis of malignancy by cell fusion. IX. Re-examination and clarification of the cytogenetic problem.

E P Evans, M D Burtenshaw, B B Brown, R Hennion, H Harris.   

Abstract

Previous experiments with crosses between malignant and diploid mouse cells had shown that the reappearance of malignancy in hybrids in which it was initially suppressed was associated in some cases with the elimination of the chromosomes 4 derived from the diploid parent cell. In others, however, this did not appear to be so. In the present study, we have re-examined the role of the diploid chromosomes 4 in the suppression of malignancy using natural polymorphisms of the centromeric heterochromatin to identify the parental origin of the chromosomes 4 in the hybrid cells. We now find that the diploid chromosomes 4 are indeed involved in the suppression of malignancy in all the tumours that we have examined, which include a carcinoma, a melanoma, a sarcoma and a lymphoma. In all crosses between these malignant tumour cells and diploid fibroblasts, there is selective pressure in vivo against the chromosomes 4 derived from the diploid cell and in favour of the chromosomes 4 derived from the malignant cell. This indicates that the chromosomes 4 in all these tumours are in some way functionally different from the chromosomes 4 of the diploid fibroblast. Reappearance of malignancy in hybrids in which it was initially suppressed may result from a reduction in the number of diploid chromosomes 4, an increase in the number of malignant chromosomes 4, or both. The gene on the diploid chromosome 4 responsible for the suppression of malignancy acts in a dose-dependent manner.

Entities:  

Mesh:

Year:  1982        PMID: 7166559     DOI: 10.1242/jcs.56.1.113

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  15 in total

1.  Tumor suppression by collagen XV is independent of the restin domain.

Authors:  Michael J Mutolo; Kirsten J Morris; Shih-Hsing Leir; Thomas C Caffrey; Marzena A Lewandowska; Michael A Hollingsworth; Ann Harris
Journal:  Matrix Biol       Date:  2012-04-16       Impact factor: 11.583

2.  Complete suppression of tumor formation by high levels of basement membrane collagen.

Authors:  Ann Harris; Henry Harris; Michael A Hollingsworth
Journal:  Mol Cancer Res       Date:  2007-12       Impact factor: 5.852

Review 3.  Suppression of the neoplastic phenotype and "anti-oncogenes".

Authors:  R Schäfer
Journal:  Blut       Date:  1987-05

Review 4.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Tumor suppression involves down-regulation of interleukin 3 expression in hybrids between autocrine mastocytoma and interleukin 3-dependent parental mast cells.

Authors:  I D Diamantis; A P Nair; H H Hirsch; C Moroni
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 6.  Hematopoietic growth and differentiation factors and the reversibility of malignancy: cell differentiation and by-passing of genetic defects in leukemia.

Authors:  L Sachs
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor.

Authors:  R S Kerbel; A E Lagarde; J W Dennis; T P Donaghue
Journal:  Mol Cell Biol       Date:  1983-04       Impact factor: 4.272

8.  Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation.

Authors:  A Stoler; N Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

Review 9.  Recessive mechanisms of malignancy.

Authors:  A R Green
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

10.  Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells.

Authors:  P J Saxon; E S Srivatsan; E J Stanbridge
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.